bioAffinity Technologies, Inc. (BIAF) Stock Profile — Insider Trades & Financials

Revenue$1.6M

Net Income-$3.1M

EPS$-7.55

Market Cap$17.6M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Maria Zannes

CEO & Executive Director

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a personâs sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

Founded: 2014
Employees: 57
Headquarters: San Antonio, Texas, United States

⚡

Core Efficiency

ROE?

-43.11%

ROA?

-28.62%

D/E Ratio?

0.51

Op. Margin?

-196.94%

📊

Profitability Ratios

Net Margin?

-196.98%

Loading company sections...

bioAffinity Technologies, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness